Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Exanthema × Clindamycin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Urinary Tract Infections 1 Urinary Bladder Neoplasms 1 Surgical Wound Infection 1 Skin Neoplasms 1 Neoplasms 1 Lung Neoplasms 1 Inflammation 1 Infections 1 Head and Neck Neoplasms 1 Exanthema 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Gels 2 Fulvestrant 2 Doxycycline 2 Dapsone 2 ruxolitinib 1 dexpanthenol 1 ceterizine hydrochloride 1 capivasertib 1 benralizumab 1 Triamcinolone Acetonide 1 Tetracycline 1 Sirolimus 1 Provitamins 1 Prednisone 1 Panitumumab 1 Minocycline 1 Loperamide 1 Irinotecan 1 IFL protocol 1 Hydrocortisone 1 Erlotinib Hydrochloride 1 Clindamycin 1 Cetuximab 1 Anti-Bacterial Agents 1 Alpelisib 1 Acitretin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00473083 2017-04-04

LUTRAERL

British Columbia Cancer Agency

Phase 2 Completed

150 enrolled 13 charts

Exanthema, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡